substitute for tirzepatide Mounjaro (tirzepatide) is a dual incretin agonist targeting both GLP-1 and GIP receptors. It improves glycaemic control by enhancing insulin secretion, suppressing glucagon, and delaying gastric emptying — which also leads to Injectable Tirzepatide | Compounded GLP-1/GIP

Patients with obesity who have type 1 diabetes are suboptimally treated for their obesity because doctors were unclear how effective the medications would be for obesity and because there were concerns regarding the risks pertaining to their type 1 diabetes, Ebaa Al Ozairi , MD, chief medical officer and head of clinical research and clinical trials at Dasman Diabetes Institute in Kuwait, and Carel le Roux, MD, PhD , professor at Ulster University School of Medicine in the U.K., told Healio

Realistic expectations regarding timeline and magnitude of improvement are essential

The most common side effects include nausea, vomiting, constipation, stomach pain, and diarrhea

Tirzepatide is a dual GLP-1 and GIP agonist peptide

Magnesium: Supporting Metabolism and Blood Sugar Control Magnesium is a crucial mineral involved in over 300 biochemical reactions in the body, including glucose metabolism and insulin sensitivity